Supplementary Appendix including cell line RRIDs and supplementary figures from Ceramide Analogue SACLAC Modulates Sphingolipid Levels and MCL-1 Splicing to Induce Apoptosis in Acute Myeloid Leukemia

Abstract

Figure S1. SACLAC reduces AC activity at lower doses than LCL204. Figure S2. SACLAC treatment increases production of multiple ceramide species in human AML cell lines. Figure S3. SACLAC is more toxic to AML cells than normal cells. Figure S4. SACLAC mechanism of action is consistent in multiple human AML cell lines. Figure S5. Exogenous ceramides induce apoptosis in human AML cell lines. Figure S6. AC knockdown alters splicing of Mcl-1 and Bim in HL-60/VCR cells via regulation of SF3B1. Figure S7. Baseline apoptosis varies based on type of electroporated content. Figure S8. Proposed model of SACLAC mechanism of action. Figure S9. IV administration of SACLAC improves delivery and lipids are shifted in mice.